Healthcare diagnostics company Quest Diagnostics (NYSE:DGX) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 7.1% year on year to $2.81 billion. The company’s full-year revenue guidance of $11.76 billion at the midpoint came in 3.3% above analysts’ estimates. Its non-GAAP profit of $2.42 per share was 2.6% above analysts’ consensus estimates.
Is now the time to buy DGX? Find out in our full research report (it’s free for active Edge members).
Quest (DGX) Q4 CY2025 Highlights:
- Revenue: $2.81 billion vs analyst estimates of $2.75 billion (7.1% year-on-year growth, 1.9% beat)
- Adjusted EPS: $2.42 vs analyst estimates of $2.36 (2.6% beat)
- Adjusted EBITDA: $574 million vs analyst estimates of $532.2 million (20.5% margin, 7.9% beat)
- Adjusted EPS guidance for the upcoming financial year 2026 is $10.60 at the midpoint, beating analyst estimates by 1.8%
- Operating Margin: 13.8%, in line with the same quarter last year
- Sales Volumes rose 8.5% year on year (13.9% in the same quarter last year)
- Market Capitalization: $22.59 billion
StockStory’s Take
Quest Diagnostics delivered a Q4 performance that exceeded Wall Street’s revenue and earnings expectations, prompting a positive market reaction. Management attributed this outcome to strong organic growth across physician, hospital, and consumer channels, with advanced diagnostics and recent partnerships like Fresenius Medical Care and Corewell Health contributing significant volume gains. CEO Jim Davis cited the company’s expansion in specialized testing—such as Alzheimer’s and autoimmune diagnostics—and collaborations that broadened geographic and health plan access as key drivers. Operational improvements, including automation and AI deployment, further supported productivity and customer experience gains.
Looking forward, Quest’s guidance for the upcoming year rests on several anticipated trends, including persistent demand for advanced diagnostics and continued expansion in consumer-initiated testing. Management believes that new collaborations in health and wellness, growth in key states through renewed payer contracts, and the scaling of digital and AI-driven initiatives will underpin future revenue momentum. CEO Jim Davis explained, “We expect organic growth to remain strong as we see tremendous uplift in our Alzheimer’s portfolio, autoimmune testing, and cardiovascular diagnostics, much of it driven by our consumer segment.” The company also anticipates further operational efficiencies and improved margins as new business lines mature and recent investments in automation are realized.
Key Insights from Management’s Remarks
Management credited Q4’s growth to robust adoption of advanced diagnostics, expanding consumer testing, and strategic collaborations with major health systems and wellness brands.
- Advanced diagnostics momentum: Quest’s advanced testing in areas like cardiometabolic, autoimmune, and brain health delivered double-digit revenue growth, with Alzheimer’s blood tests and the Analyzer solution for autoimmune disorders gaining strong adoption among clinicians and primary care providers.
- Consumer testing expansion: The company’s direct-to-consumer platform, questhealth.com, exceeded 35% growth for the year, now offering over 150 tests and new biomarker panels. Collaborations with wellness and wearable brands, such as WHOOP and Oura, further expanded the addressable consumer market, driving both volume and margin benefit.
- Strategic partnerships drive volume: Agreements with Fresenius Medical Care and Corewell Health added significant patient volumes, although at lower revenue per test. The Corewell CoLab initiative is expected to generate $1 billion in annual revenue in 2026, demonstrating the growing importance of hospital collaborations.
- Operational efficiencies through technology: Automation and AI initiatives, including the INFIGURATE program and digital sample processing, yielded 3% annual cost savings and productivity improvements. AI tools reduced routine logistics calls by up to 50% and are expected to further streamline lab and courier operations.
- Regulatory developments and advocacy: The delay in PAMA (Protecting Access to Medicare Act) rate cuts until 2026 provided short-term relief, but management emphasized continued advocacy for structural reforms via the RESULTS Act to ensure sustainable reimbursement rates. The outcome of these legislative efforts remains a key industry consideration.
Drivers of Future Performance
Quest’s outlook is shaped by continued growth in advanced diagnostics, consumer testing, and operational improvements, balanced by margin pressures from new collaborations and investments.
- Growth in consumer and advanced diagnostics: Management expects consumer-initiated testing and high-value diagnostic areas like Alzheimer’s, oncology, and autoimmune disease to continue expanding at rates exceeding 20%, aided by new tests and digital partnerships.
- Margin trajectory and new business ramp: While overall operating margin is expected to expand, the onboarding of large-scale collaborations such as Corewell Health will exert downward pressure, as these volumes carry lower initial margins. Project Nova, an order-to-cash initiative, will also create near-term cost headwinds but is expected to improve efficiency over time.
- Regulatory and reimbursement landscape: The ongoing delay of PAMA cuts offers temporary stability, but persistent uncertainty around future reimbursement methodologies and the implementation of the RESULTS Act present risks. Management is monitoring evolving payer dynamics, particularly in states where Quest is regaining network access, as these will influence share gains and utilization.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will closely monitor (1) the ramp and margin progression of large-scale collaborations like Corewell and Fresenius, (2) sustained double-digit growth in consumer-initiated and advanced diagnostics testing, and (3) the impact of legislative developments, particularly around PAMA and the RESULTS Act, on reimbursement stability. The pace of operational efficiency gains from automation and AI initiatives will also be key.
Quest currently trades at $201.78, up from $191.25 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).
Now Could Be The Perfect Time To Invest In These Stocks
The market’s up big this year - but there’s a catch. Just 4 stocks account for half the S&P 500’s entire gain. That kind of concentration makes investors nervous, and for good reason. While everyone piles into the same crowded names, smart investors are hunting quality where no one’s looking - and paying a fraction of the price. Check out the high-quality names we’ve flagged in our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.